Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder

AstraZeneca90 enrolled

Overview

The purpose of this study is to evaluate how effective quetiapine versus placebo is when added to an existing therapy, in reducing the symptoms of PTSD.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Post-Traumatic Stress Disorder

Interventions

Quetiapine FumarateDRUG

oral flexible dose

quetiapine fumarate placeboDRUG

oral 0 mg

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hospitalised and non-hospitalised patients / Veteran or Civilian / Have had symptoms of PTSD for a minimum of 12 months prior to giving consent to the study Exclusion Criteria: * History of psychotic condition / quetiapine or other anti-psychotics not worked previously / Taking prohibited medications (mood stabilizers / substance abuse)

Locations (3)

Research Site

Brisbane, Queensland, Australia

Research Site

Adelaide, South Australia, Australia

Research Site

Melbourne, Victoria, Australia

Outcomes

Primary Outcomes

Clinical Administered PTSD Scale (CAPS2)

Secondary Outcomes

Hamilton Depression Scale (HAM-D)

Hamilton Anxiety Scale (HAM-A)

Posttraumatic Stress Disorder Checklist (PCL)

Clinical Global Impressions (CGI)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.